Lopinavir/ritonavir in the treatment of HIV-1 infection: A review

Ashish Chandwani, Jonathan Shuter

Research output: Contribution to journalReview article

51 Scopus citations

Abstract

Lopinavir/ritonavir is the first and only coformulated HIV-1 protease inhibitor (PI). Large clinical trials have demonstrated lopinavir/ ritonavir's clinical efficacy in both antiretroviral-naïve and -experienced patients. The immunologic and virologic benefits of treatment with this agent have been proven in HIV-infected adults, adolescents, and children. Smaller studies support the use of lopinavir/ ritonavir monotherapy as a therapeutic option in certain patients. The drug is characterized by a high genetic barrier to resistance, and appears to be more forgiving of non-adherence than earlier, unboosted PIs. The most frequent side effects observed are diarrhea, nausea, and vomiting. These gastrointestinal adverse effects are generally mild to moderate. Metabolic derangements, including hyperlipidemia and glucose intolerance, have also been observed in lopinavir/ritonavir recipients. As the menu of available antiretroviral agents continues to expand, lopinavir/ritonavir remains a proven and effective drug for the treatment of HIV infection.

Original languageEnglish (US)
Pages (from-to)1023-1033
Number of pages11
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number5
StatePublished - Dec 1 2008

    Fingerprint

Keywords

  • Antiretroviral
  • HIV
  • Kaletra®
  • Lopinavir/ritonavir
  • Protease inhibitor

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Cite this